Pal SK - Search Results

1

Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma.

Dizman N, Hsu J, Bergerot PG, Gillece JD, Folkerts M, Reining L, Trent J, Highlander SK, Pal SK. Dizman N, et al. Among authors: pal sk. Cancer Med. 2021 Jan;10(1):79-86. doi: 10.1002/cam4.3569. Epub 2020 Nov 1. Cancer Med. 2021. PMID: 33135866 Free PMC article. Clinical Trial.

2

The role of targeting mammalian target of rapamycin in lung cancer.

Pal SK, Figlin RA, Reckamp KL. Pal SK, et al. Clin Lung Cancer. 2008 Nov;9(6):340-5. doi: 10.3816/CLC.2008.n.049. Clin Lung Cancer. 2008. PMID: 19073516 Review.

3

Renal cell carcinoma therapy in 2010: many options with little comparative data.

Pal SK, Figlin RA. Pal SK, et al. Clin Adv Hematol Oncol. 2010 Mar;8(3):191-200. Clin Adv Hematol Oncol. 2010. PMID: 20400934 Review.

4

Targeted therapies for non-small cell lung cancer: an evolving landscape.

Pal SK, Figlin RA, Reckamp K. Pal SK, et al. Mol Cancer Ther. 2010 Jul;9(7):1931-44. doi: 10.1158/1535-7163.MCT-10-0239. Epub 2010 Jun 22. Mol Cancer Ther. 2010. PMID: 20571071 Free PMC article. Review.

5

Targeted therapies for renal cell carcinoma: understanding their impact on survival.

Pal SK, Figlin RA. Pal SK, et al. Target Oncol. 2010 Jun;5(2):131-8. doi: 10.1007/s11523-010-0145-6. Epub 2010 Jul 15. Target Oncol. 2010. PMID: 20632214 Review.

6

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.

Pal SK, Figlin RA. Pal SK, et al. Clin Med Insights Oncol. 2010 Jun 9;4:43-53. doi: 10.4137/cmo.s1590. Clin Med Insights Oncol. 2010. PMID: 20711245 Free PMC article.

7

Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Pal SK, Kortylewski M, Yu H, Figlin RA. Pal SK, et al. Mol Cancer Ther. 2010 Dec;9(12):3115-25. doi: 10.1158/1535-7163.MCT-10-0873. Epub 2010 Nov 15. Mol Cancer Ther. 2010. PMID: 21078774 Free PMC article. Review.

8

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.

Pal SK, Figlin RA. Pal SK, et al. Target Oncol. 2011 Mar;6(1):5-16. doi: 10.1007/s11523-011-0172-y. Epub 2011 Apr 12. Target Oncol. 2011. PMID: 21484496 Free PMC article. Review.

9

Systemic therapies for metastatic renal cell carcinoma in older adults.

Pal SK, Vanderwalde A, Hurria A, Figlin RA. Pal SK, et al. Drugs Aging. 2011 Aug 1;28(8):635-49. doi: 10.2165/11592880-000000000-00000. Drugs Aging. 2011. PMID: 21812499 Free PMC article. Review.

10

Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS.

Pal SK, Vogelzang NJ. Pal SK, et al. Clin Genitourin Cancer. 2011 Sep;9(1):3-5. doi: 10.1016/j.clgc.2011.06.003. Epub 2011 Aug 3. Clin Genitourin Cancer. 2011. PMID: 21816688 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,141 results

Search Page

Filters